期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MicroRNA在乳腺癌内分泌耐药中的研究新进展 被引量：4

Progression of miRNA in endocrine therapy-resistance breast cancer
下载PDF
导出
摘要 内分泌治疗可显著改善雌激素受体阳性的乳腺癌患者的无病生存期和总生存期,但内分泌耐药是导致治疗失败的重要原因。微小RNA(microRNA,miRNA)是肿瘤研究领域中的热点,新近研究证实miRNA的表达变化是乳腺癌耐药机制之一。miRNA通过上调药物外排转运、抗凋亡蛋白、调节多药耐药信号传导网络等方式促成上皮-间质转化并形成肿瘤干细胞。miRNA亦可能通过调节雌激素受体α表达、受体酪氨酸激酶信号传导、细胞生存信号及细胞凋亡等途径引发耐药。miRNA可能成为激素受体阳性乳腺癌的预后因子、内分泌治疗疗效评估的预测因子以及新的靶点。 Endocrine therapy is most effective adjuvant treatment for estrogen receptor（ ER） positive breast cancer,significantly improving disease free survival and overall survival. However,endocrine treatment failure due to drug resistance leads to poor prognosis in some patients. Recently,microRNA（ miRNA） is becoming a hotspot in the field of cancer research. More and more studies demonstrated that the expression and regulation of various miRNA was one of the key factors of drug resistance mechanisms of breast cancer. MiRNA stimulated epithelial-mesenchymal transition and cancer stem cells formation by modulating drug efflux transporters,anti-apoptotic protein and multidrug resistance signal transduction networks. Recent studies found that miRNA could control endocrine resistance mainly by regulating ERα expression,tyrosine kinase receptor signal transduction,survival signaling and apoptosis pathway.Many studies showed that miRNA might be prognostic factor for hormone receptor positive breast cancer and predict factor for assessing the efficacy of endocrine therapy. As a new molecular marker,it is possible that miRNA can provide a new target to overcome endocrine therapy resistance so as to further improve endocrine therapy efficient of breast cancer.
作者 陈靓昱 张清媛
机构地区 哈尔滨医科大学附属肿瘤医院肿瘤内科
出处 《临床肿瘤学杂志》 CAS 2014年第12期1147-1150,共4页 Chinese Clinical Oncology
关键词 微小RNA 乳腺癌 内分泌治疗 耐药 MicroRNA Breast cancer Endocrine therapy Resistance
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1American Cancer Society. Cancer Facts & Figures 2013[ R]. At- lanta: American Cancer Society, 2013.
  • 2江昊,王甜甜,周涛.PIK3CA和C-KIT基因突变与伴腋窝淋巴结转移乳腺癌临床病理特征及预后的关系[J].临床肿瘤学杂志,2014,19(2):112-116. 被引量：5
  • 3Early Breast Cancer Trialists' Collaborative Group ( EBCTCG ) ,Peto R, Davies C, et al. Comparisons between different polyche- motherapy regimens for early breast cancer: meta-analyses of long- term outcome among 100,000 women in 123 randomised trials [J]. Lancet, 2012, 379(9814) :432-444.
  • 4Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer[ J]. Annu Rev Med, 2011, 62:233-247.
  • 5Bartel DP. MicroRNAs : target recognition and regulatory functions [J]. Cell, 2009, 136(2) :215-233.
  • 6Pasquinelli AE. MicroRNAs and their targets: recognition, regu- lation and an emerging reciprocal relationship [ J ]. Nat Rev Genet, 2012, 13(4) :271-282.
  • 7Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic : progress in validating and targeting microRNAs for cancer therapy [ J]. Nat Rev Cancer, 2011, 11 (12) : 849 -864.
  • 8Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer[J]. Curr Genomics, 2010, 11(7) :537-561.
  • 9Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in human cancer[ J]. Adv Exp Med Biol, 2013, 774:1-20.
  • 10Petrovic N, Mandusic V, Stanojevic B, et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion[ J]. Med On- col, 2014, 31(3):867.

二级参考文献16

  • 1Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway incancer [ J ]. Annu Rev Pathol, 2009, 4 : 127-150.
  • 2L6pez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phe- notype and cancer-specific mortality [ J ]. Im J Cancer, 2010, 126(5) :1121-1131.
  • 3Benvenuti S, Frattini M, Arena S, et al. P1K3CA cancer muta- tions display gender and tissue specificity patterns[ J]. Hum Mu- tat, 2008, 29(2) : 284-288.
  • 4Lemmon MA, Ferguson KM. A new twist in the transmembrane signaling tool-kit[J]. Cell, 2007, 130(2): 213-215.
  • 5Guido H, Mathias G, Udo S, et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression[J]. Clin Chem, 2010, 56(12) :1845-1853.
  • 6Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adju- vant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients[J]. Cancer, 2006, 106( 11 ) : 2337-2344.
  • 7Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer associated PIK3CA mutations are oncogenie in mammary epitbe- lialcells[J]. Cancer Res, 2005, 65 (23) : 10992-11000.
  • 8Samuels Y, Wang Z, Bardelli A, et al. High frequency of muta- tions of the P1K3CA gene in human cancers[ J]. Science, 2004, 304(5670) :554-554.
  • 9Kataoka Y, Mukohara T, Shimada H, et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2- targeted agents in HER2-amplified breast cancer cell lines [J].Ann Oncol, 2010, 21(2): 255-262.
  • 10Bozhanov SS, Angelova SG, Krasteva ME, et al. Alterations in p53, BRCA l, ATM, PIK3CA, and HER2 genes and their effect in modifying elinicopathological characteristics and overall survival of Bulgarian patients with breast cancer [ J ]. J Cancer Res Clin Oncol, 2010, 136( 11 ) : 1657-1669.

共引文献4

同被引文献31

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J ]. CA Cancer J Clin, 2011, 61(2) :69-90.
  • 2Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 sta- tus, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101 (10) :736-750.
  • 3Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of Ameri- can Pathologists clinical practice guideline update [ J ]. Arch Pathol Lab Med,2014,138(2) :241-256.
  • 4Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub- types-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011 [ J ]. Ann Oncol, 2011, 22 (8) : 1736 - 1747.
  • 5Ortiz AP, Frias O, P6rez J, et al. Breast cancer molecular sub- types and survival in a hospital-based sample in Puerto Rico[ J]. Cancer Med, 2013, 2(3) :343-350.
  • 6Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of hu- man breast tumours[J]. Nature, 2000, 406(6797) :747-752.
  • 7O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor sub- types,race, and long-term survival in the Carolina Breast Cancer Study[J].Clin Cancer Res, 2010, 16(24) :6100-6110.
  • 8Kruijf EMD, Bastiaannet E, Ruberti F, et al. Comparison of fre- quencies and prognostic effect of molecular subtypes between oung and elderly breastcancer patients[ J]. Mol Oncol, 2014, 8 (5) :1014-1025.
  • 9Patel TA, Colon-Otero G, Bueno HC, et al. Breast cancer in Latinas : gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups[J].Oncologist, 2010, 15(5): 466-475.
  • 10Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome[ J]. J Nail Cancer Ins, 2005, 97(6) :439-448.

引证文献4

二级引证文献15

临床肿瘤学杂志
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部